Total trials
100
Active
16
Phase 3
5
Total enrollment
269,707
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre | — | — | — | — | — | 1 |
Next readouts
- 2025-05-25
Top conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma5
- Primary Aldosteronism5
- Stroke4
- Hypertension3
- Frailty3
- Sexual Dysfunction3
- Endothelial Dysfunction3
- Quality of Life3
Frequently asked questions about Changi General Hospital
- How many clinical trials does Changi General Hospital have on ClinicalTrials.gov?
- Changi General Hospital is listed as the lead sponsor on 100 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Changi General Hospital's trials are in Phase 3?
- 5 of Changi General Hospital's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Changi General Hospital focus on?
- Changi General Hospital's most-studied conditions on ClinicalTrials.gov are Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Stroke, Hypertension, Frailty.
- When are Changi General Hospital's next clinical trial readouts?
- Changi General Hospital has 1 upcoming primary-completion readout tracked here; the soonest is “11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours”, expected around 2025-05-25.